A clinical trial of NG-348, an "armed" oncolytic virus for the treatment of solid tumors.
Phase of Trial: Phase I
Latest Information Update: 15 Dec 2017
At a glance
- Drugs NG-348 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 15 Dec 2017 New trial record
- 12 Dec 2017 According to a PsiOxus Therapeutics media release, the Clinical Trial Application for NG-348 for the treatment of solid tumors, has been approved.